Key Highlights

  • Per the third quarter 2026 company release, net Leverage is guided at 4.0x and total Debt sits at USD 3.3 billion, the backdrop for the USD 0.29 quarterly payment.
  • On All In adjusted EPS, the payout sits at a calculated 49% of the USD 2.35 guidance midpoint for 2026. On cash, though, free Cash Flow for nine months was roughly USD 19.6 million (calculated), set against USD 120.3 million paid.
  • Third quarter All In net sales slipped 5.2% to USD 988.6 million, with an adjusted Operating Margin of 13.1%, while Core adjusted EPS guidance for 2026 is USD 2.15 to USD 2.35.
  • Two portfolio moves are in play, a sale of Infant Formula worth as much as USD 175 million and a still-ongoing review of Oral Care, both sharpening the consumer self-care focus, while USD 275 million to USD 375 million of fourth quarter Impairment is on the horizon.

Payout Level, Declaration Timing and Annualized Rate at Perrigo Company plc (NYSE:PRGO)

The July 30, 2026 announcement from Perrigo set the quarterly payment at USD 0.29 per share, which comes to USD 1.16 annualized on a calculated basis. USD 40.0 million was paid in the third quarter, and across the first nine months of 2026 the total reached USD 120.3 million. Measured against All In adjusted EPS guidance, whose midpoint is USD 2.35, the yearly amount equates to a calculated payout of 49%.

Sales Decline, Margin Trends and Cash Conversion Gap at Perrigo Company plc (NYSE:PRGO)

Perrigo Company plc (NYSE:PRGO) reported third quarter net sales of USD 988.6 million, a 5.2% drop, and on an organic basis All In sales eased 1.9% to USD 994 million. The company generated USD 129.1 million of adjusted operating income, which is a 13.1% margin, while All In adjusted EPS fell 25.0% to USD 0.60. Cash from operations reached USD 96 million, and after USD 18 million of Capital spending, calculated free cash flow was about USD 78 million. Over nine months, the cash generated from operations of USD 65.2 million minus USD 45.6 million of capex left about USD 19.6 million (calculated), which sits under the dividends paid. The company's outlook presumes operating cash will land in the low-to-mid 60% range relative to adjusted net income.

Debt Load, Net Leverage and Impairment Charges at Perrigo Company plc (NYSE:PRGO)

Perrigo Company plc (NYSE:PRGO) held USD 436.6 million of cash and equivalents at September 26, 2026, against about USD 3.3 billion of total debt, made up of USD 3,282.8 million long-term and USD 11.3 million current. Management expects net leverage near 4.0x adjusted EBITDA, and net interest expense around USD 162 million. Nine-month impairments totaled USD 335.9 million, and the GAAP net result was a loss of USD 351.6 million, equal to USD 2.53 a diluted share. Downside factors include retailers being careful with stock levels, soft European Demand and Leadership run by an interim chief executive.

Where Things Stand

On an Earnings basis, the payout looks comfortable, but on cash it is not yet covered in 2026. Perrigo Company plc (NYSE:PRGO) is paying USD 1.16 a year against a Balance Sheet carrying about USD 3.3 billion of debt, and cash conversion has been uneven. Management lifted All In adjusted EPS guidance to a USD 2.25 to USD 2.45 range, against a previous USD 2.00 to USD 2.30 range, and trimmed the Core range to USD 2.15 to USD 2.35, down from USD 2.25 to USD 2.55. Selling Infant Formula brings in an upfront USD 40 million and as much as USD 135 million more, tied to net sales targets running through 2030. Interim Chief Executive Albert Manzone points to growth in Market Share for American store Brand over-the-counter lines and for core European labels. Whether cash covers the payout hinges on a firmer second half and reduced restructuring spending.